#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Crigler-Najjar syndrome Endometrial cancer recurrent Cholangiosarcoma Chondrodystrophy Anaplastic large cell lymphoma T- and null-cell types Myeloproliferative neoplasm Infective uveitis Follicle centre lymphoma follicular grade I II – III refractory Gastrointestinal disorder Hypophosphatasia Acute myeloid leukaemia (in remission) Thalassaemia alpha Heritable pulmonary arterial hypertension Hairy cell leukaemia Thrombotic thrombocytopenic purpura More trials…

    Learn about Rare Diseases

    Langerhans’ cell histiocytosis – Treatment Isodicentric chromosome 15 syndrome – Basic Information Acquired haemophilia – Diagnostics Angiosarcoma metastatic – Life with Disease Retinoblastoma – Treatment Noonan syndrome – Treatment Rett syndrome – Diagnostics Medulloblastoma recurrent – Treatment Wolfram syndrome Chondrosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bepranemab Cetrimide Litifilimab Relebactam ARI0008 Tegafur XMAB942 Naproxen Ozanimod Munc-Cd34 Ponsegromab Erythromycin Lactobionate Empasiprubart Bay 2927088 Brigatinib Exl01 Teclistamab Nesolicaftor Clodronate Disodium Tremelimumab More therapies…

    Learn about Your Condition

    Toxic epidermal necrolysis Limb reduction defect Neoplasm Perinatal depression Pruritus Polycystic liver disease Colitis Choreoathetosis Status epilepticus Transferrin decreased Post-traumatic stress disorder Neonatal asphyxia Psychotic disorder Alveolar proteinosis Leukoencephalopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Psoriatic arthropathy

  • Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

    Recruiting

    3 1 1 1 1
    Investigated Drugs:
    • Secukinumab
    Belgium Bulgaria Czechia Germany Italy Poland +2

  • A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Sonelokimab
    Bulgaria Croatia Czechia Estonia Finland France +10

  • A Study of Guselkumab and Ciclosporin in Patients with Early Psoriatic Arthritis Transitioning from Skin to Joint Disease

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Ciclosporin
    • Guselkumab
    Italy

  • Testing the Safety of Combining Tocilizumab with Other Biologic Drugs in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    • Psoriatic arthropathy
    Investigated Drugs:
    • Tocilizumab
    Spain

  • Study to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Bimekizumab
    Germany Spain

  • Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Giant cell arteritis
    • Polymyalgia rheumatica
    • Juvenile idiopathic arthritis
    Investigated Drugs:
    • Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
    Sweden
Previous Page
1 2 3 4 5 6 … 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!